AAV Gene Therapy for TMPRSS3 Hearing Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hearing loss and deafness, particularly those caused by genetic mutations in the TMPRSS3 and LOXHD1 genes, lack effective pharmacological interventions, with cochlear implants being costly and insufficient for many individuals, especially in low-income countries, and there is a need for alternative therapeutic options that can prevent or delay the onset of hearing loss.
Innovation Solution
Development of pharmaceutical compositions and methods involving adeno-associated viral vectors (AAV2) to deliver nucleic acid sequences encoding functional TMPRSS3 or LOXHD1 into the inner ear, using promoters like the human cytomegalovirus promoter, to restore gene function and promote hair cell survival, potentially combined with other therapeutic agents or cochlear implantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cochlear implantation is used to treat hearing loss, then hearing function is restored, but the cost becomes prohibitive and accessibility is limited
Solution Approach 1:
The patent replaces the mechanical/electrical cochlear implant system with a biological gene therapy system. Adeno-associated viral vectors deliver functional copies of the TMPRSS3 or LOXHD1 genes to the inner ear, allowing the body's own cells to produce the missing protein and restore hair cell function naturally, eliminating the need for expensive implant devices
Solution Approach 2:
The patent changes the fundamental treatment parameter from external device intervention to internal biological correction. By modifying the genetic parameter (delivering functional gene copies), the treatment addresses the root cause of hearing loss at the molecular level, potentially providing permanent correction without ongoing device costs
2Productivity
If cochlear implants are produced at current rates, then manufacturing is manageable, but the quantity is insufficient to meet the demand of afflicted individuals
Solution Approach 1:
The gene therapy approach enables the body's cells to self-correct the genetic defect. Once the functional gene is delivered via viral vector, the patient's inner ear cells autonomously produce the missing protein, eliminating the need for external device maintenance, power sources, or follow-up interventions that cochlear implants require
3Reliability
If gene therapy is used to restore gene function, then hearing loss can be prevented or treated, but the complexity of delivering functional genes to the inner ear increases
Solution Approach 1:
The patent uses adeno-associated viral vectors as intermediary carriers to deliver functional gene copies to inner ear cells. These viral vectors naturally infect target cells and transfer genetic material efficiently, solving the delivery complexity problem by harnessing nature's own gene transfer mechanism rather than attempting artificial delivery methods
Solution Approach 2:
The adeno-associated viral vector system serves multiple functions: it protects the genetic material during delivery, efficiently enters target cells, integrates or maintains the therapeutic gene, and enables long-term expression. This multi-functional vector system simplifies the overall therapy compared to requiring separate components for each function
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are compositions and methods that useful in the treatment and/or prevention of hearing loss caused by genetic mutation of the TMPRSS3 gene or the LOXHDl gene. The compositions and methods disclosed herein use adeno-associated viral (AAV) vector gene delivery of TRMPSS3 or LOXHDl into the inner ear to restore activity of the TMPRSS3 gene or the LOXHDl gene, respectively, promote hair cell survival and restore hearing in patients suffering from hearing loss.